

ACell enters Chinese distribution agreement for wound management

09 April 2019 | News | By Sonali Wankhade

Weihai Jierui gets exclusive rights for sale, marketing, and distribution of ACell's devices in mainland China and Hong Kong for 10 years after marketing clearance



ACell, a leading regenerative medicine company has entered into an exclusive long-term product supply and distribution agreement with First Horizon, LLC and Weihai Jierui Medical Products Co., Ltd. a division of Shandong Weigao Group Medical Polymer Company, Ltd. Weihai Jierui is a leading manufacturer and distributor of medical devices in China.

The terms of the distribution agreement grant exclusive rights to Weihai Jierui for the sale, marketing, and distribution of ACell's MicroMatrix® and Cytal® Wound Matrix devices in mainland China and Hong Kong for 10 years after marketing clearance. Weihai Jierui has also committed to collaborate with ACell on obtaining regulatory approvals necessary prior to commercialization.

"ACell is excited to be entering this partnership, and we look forward to working together with Weihai Jierui to address the rapidly growing need for effective wound management products in China," said Nino Pionati, ACell Vice President, International and Business Development.

"This agreement represents not only a significant milestone in ACell's global expansion, but the initiation of an important partnership that will help Chinese patients and offer substantial growth prospects for both of our organizations." said ACell CEO Patrick McBrayer.